Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

2(40.0%)

N/A

1(20.0%)

5Total

Phase 2(2)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03663725Phase 3Active Not Recruiting

Treatment Intensification With Temozolomide in Adults With a Glioblastoma

Role: collaborator

NCT05102747Not ApplicableRecruiting

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.

Role: collaborator

NCT02444000Phase 3Completed

gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas

Role: collaborator

NCT04397575Completed

The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients

Role: collaborator

NCT01022918Phase 2Completed

Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma

Role: collaborator

NCT01242566Phase 2Completed

Temozolomide in Elderly Patients With KPS < 70

Role: collaborator

All 6 trials loaded